Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand.

Moolphate S, Lawpoolsri S, Pungrassami P, Sanguanwongse N, Yamada N, Kaewkungwal J.

Glob J Health Sci. 2013 Mar 25;5(4):60-70. doi: 10.5539/gjhs.v5n4p60.

3.

Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV.

Date AA, Vitoria M, Granich R, Banda M, Fox MY, Gilks C.

Bull World Health Organ. 2010 Apr;88(4):253-9. doi: 10.2471/BLT.09.066522. Epub 2009 Oct 23.

4.

Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience.

Costenaro P, Massavon W, Lundin R, Nabachwa SM, Fregonese F, Morelli E, Alowo A, Nannyonga Musoke M, Namisi CP, Kizito S, Bilardi D, Mazza A, Cotton MF, Giaquinto C, Penazzato M.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e1-8. doi: 10.1097/QAI.0000000000000806.

PMID:
26761275
5.

Physician adherence to isoniazid preventive therapy guidelines for HIV-infected patients in Thailand.

Hiransuthikul N, Hiransuthikul P, Nelson KE, Jirawisit M, Paewplot R, Kasak S.

Southeast Asian J Trop Med Public Health. 2005 Sep;36(5):1208-15.

PMID:
16438147
6.

The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.

Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM.

BMC Public Health. 2015 Apr 10;15:346. doi: 10.1186/s12889-015-1719-0.

7.

Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues.

Aït-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, Chiang CY, Clevenbergh P, Dlodlo R, Enarson DA, Enarson P, Ferroussier O, Fujiwara PI, Harries AD, Heldal E, Hinderaker SG, Kim SJ, Lienhardt C, Rieder HL, Rusen ID, Trébucq A, Van Deun A, Wilson N.

Int J Tuberc Lung Dis. 2009 Aug;13(8):927-35.

PMID:
19723371
8.

Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.

Yirdaw KD, Jerene D, Gashu Z, Edginton ME, Kumar AM, Letamo Y, Feleke B, Teklu AM, Zewdu S, Weiss B, Ruff A.

PLoS One. 2014 Aug 8;9(8):e104557. doi: 10.1371/journal.pone.0104557. eCollection 2014.

9.

Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries.

Gupta S, Granich R, Date A, Lepere P, Hersh B, Gouws E, Samb B.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1149-58. doi: 10.5588/ijtld.13.0889. Review.

PMID:
25216827
10.

Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.

Shayo GA, Moshiro C, Aboud S, Bakari M, Mugusi FM.

BMC Infect Dis. 2015 Aug 26;15:368. doi: 10.1186/s12879-015-1085-7.

11.

Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.

Ayele HT, Mourik MS, Debray TP, Bonten MJ.

PLoS One. 2015 Nov 9;10(11):e0142290. doi: 10.1371/journal.pone.0142290. eCollection 2015. Review.

12.

Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia.

Zaeh S, Kempker R, Stenehjem E, Blumberg HM, Temesgen O, Ofotokun I, Tenna A.

Int J Tuberc Lung Dis. 2013 Nov;17(11):1396-401. doi: 10.5588/ijtld.13.0315.

13.

Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study.

Mindachew M, Deribew A, Memiah P, Biadgilign S.

Pan Afr Med J. 2014 Jan 17;17:26. doi: 10.11604/pamj.2014.17.26.2641. eCollection 2014.

14.

Isoniazid preventive therapy programmes for healthcare workers in India: translating evidence into policy.

Raj R, Prasad H, Arya BK, Bhattacharya SD.

Natl Med J India. 2011 Jul-Aug;24(4):201-7.

PMID:
22208138
15.

Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia.

Mindachew M, Deribew A, Tessema F, Biadgilign S.

BMC Public Health. 2011 Dec 12;11:916. doi: 10.1186/1471-2458-11-916.

16.

Tuberculosis screening and isoniazid preventive therapy implementation: a Brazilian experience.

Swaminathan S, Chandrasekaran P.

Expert Rev Anti Infect Ther. 2014 Mar;12(3):289-92. doi: 10.1586/14787210.2014.880338. Epub 2014 Jan 23.

PMID:
24455973
17.

Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.

Briggs MA, Emerson C, Modi S, Taylor NK, Date A.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S297-305. doi: 10.1097/QAI.0000000000000497. Review.

PMID:
25768869
18.

Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.

van Griensven J, Choun K, Chim B, Thai S, Lorent N, Lynen L.

Trop Med Int Health. 2015 Dec;20(12):1823-31. doi: 10.1111/tmi.12609. Epub 2015 Oct 19.

19.

Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure.

Mills HL, Cohen T, Colijn C.

J R Soc Interface. 2011 Oct 7;8(63):1510-20. doi: 10.1098/rsif.2011.0160. Epub 2011 Apr 20.

20.

Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.

Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O, Vernon A, Wells CD, Samandari T.

Am J Respir Crit Care Med. 2010 Jul 15;182(2):278-85. doi: 10.1164/rccm.200911-1783OC. Epub 2010 Apr 8.

PMID:
20378730

Supplemental Content

Support Center